Core Viewpoint - QHSLab Inc. is enhancing its governance framework by adding independent board members to align with shareholder interests and prepare for future listing requirements [1][2][3] Governance Evolution - The company has initiated a structured selection process for independent directors to strengthen governance practices and support long-term growth objectives [2][3] - The addition of independent directors is expected to enhance oversight and broaden strategic perspectives, aiding in customary corporate approvals as the company prepares for potential uplisting [3] Capital Structure Improvements - Recent actions taken by the company include the elimination of legacy convertible debt, reduction of interest expenses, and completion of a funding transaction aimed at supporting growth while limiting dilution [4] - These measures are designed to improve transparency, strengthen the balance sheet, and align management with shareholder interests [4] Leadership Commentary - The President and CEO of QHSLab emphasized the importance of evolving the governance structure to strengthen oversight and support future capital market objectives, reflecting the company's progress [5] Company Overview - QHSLab, Inc. is a digital health infrastructure company that provides preventive screening, assessment, and workflow solutions for primary care practices, enabling scalable and reimbursable care delivery [6]

Core Insights - The company reported a revenue of $1.99 million for the nine months ended September 30, 2025, reflecting a 32% year-over-year increase [3][12] - The company has eliminated most of its convertible debt, reducing it from approximately $1.4 million to $20,000, which is expected to decrease annual interest expenses by over $250,000 [4] - The company ended 2025 with approximately $630,000 in cash and believes it exited the year in a cash-flow-positive operating position [5][12] Financial Performance - Revenue for the nine months ended September 30, 2025, was $1.99 million, a 32% increase year-over-year [3] - Gross profit for the same period was $1.32 million, resulting in a gross margin of approximately 66% [12] - Net operating income before interest was reported at $95,738 [12] Balance Sheet and Capital Structure - The company has simplified its balance sheet by nearly eliminating convertible debt [4] - As of the release date, the company has 13,418,899 shares of common stock outstanding, with approximately 2,429,525 shares constituting the public trading float [6] - Approximately 2,301,565 restricted common shares are included in the outstanding shares, subject to Rule 144 restrictions [7] Operational Outlook - Management anticipates improved operating leverage entering 2026, expecting to report net income after interest, amortization, and depreciation for the year ended December 31, 2025 [9]

Core Viewpoint - QHSLab Inc. has successfully completed a $500,000 private placement, enhancing its balance sheet and shifting focus from debt management to growth execution following the retirement of legacy convertible debt [1][2][5] Financial Developments - The company retired over $1.4 million of legacy convertible notes, which had an 18% default interest rate and conversion rights at $0.20 per share, thus eliminating potential dilution and reducing annual interest expenses by over $200,000 [2][3] - The recent capital injection and debt retirement have improved the company's liquidity and financial flexibility, allowing it to support working capital needs and pursue growth initiatives [3][5] Growth Strategy - QHSLab plans to execute targeted sales and marketing efforts to expand its medical practice client base, enhance onboarding and implementation capacity, and improve customer support activities [3] - The company aims to increase its physician client base, recurring assessment volume, revenues, and operational efficiencies [3] Investor Insights - The $500,000 placement consisted entirely of newly issued common stock and long-term warrants, aligning investors with management's long-term growth strategy [4] - Management views this financing as a significant turning point, having removed a major source of dilution and interest expense while replacing it with clean equity capital [5] Recent Financial Performance - For the first nine months of 2025, QHSLab reported revenues of $1.99 million, reflecting a 32% year-over-year increase, and a gross profit of $1.32 million, resulting in a 66% gross margin [6]

Core Viewpoint - QHSLab Inc. has successfully completed a $500,000 private placement, enhancing its balance sheet and shifting focus from debt management to disciplined growth execution [1][4]. Financial Restructuring - The company retired over $1.4 million of legacy convertible notes, which had an 18% default interest rate and conversion rights at $0.20 per share, eliminating potential dilution and over $200,000 in annual interest expenses [2][3]. - The combination of eliminating high-cost convertible debt and securing new equity capital has improved the company's liquidity and financial flexibility [3]. Growth Strategy - QHSLab plans to utilize the new capital for targeted sales and marketing efforts, expanding its medical practice client base, onboarding capacity, and customer support activities [3]. - The company aims to increase its physician client base, recurring assessment volume, revenues, and operational efficiencies [3]. Investor Confidence - The recent capital raise was entirely in common stock and long-term warrants, aligning investors with management's long-term growth strategy [4]. - An investor expressed confidence in QHSLab's trajectory, indicating a positive outlook on the company's future [4]. Management Commentary - The President and CEO emphasized that the financing, while modest, marks a significant turning point for the company, allowing it to focus on scaling its digital medicine programs and driving recurring revenue growth [5]. - The company enters 2026 with a cleaner capital structure, positioning it to prioritize disciplined growth and shareholder value [5]. Recent Financial Highlights - For the first nine months of 2025, QHSLab reported revenues of $1.99 million, a 32% increase year-over-year, and a gross profit of $1.32 million, reflecting a 66% gross margin [6].